Utah Medical Products (UTMD) EBIT Margin (2010 - 2026)

Utah Medical Products' EBIT Margin history runs 17 years deep, the most recent figure standing at 29.41% for Q1 2026.

• In Q1 2026, EBIT Margin fell 306.0% year-over-year to 29.41%; the TTM figure through Mar 2026 stood at 5.03% (down 2773.0% YoY), while the FY2025 annual figure was 6.43%, down 40.0% from the prior year.
• EBIT Margin was 29.41% for Q1 2026 at Utah Medical Products, up from 71.69% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 39.68% in Q3 2022 to a low of 89.13% in Q4 2022.
• Historically, EBIT Margin has averaged 13.12% across 5 years, with a median of 32.47% in 2025.
• The sharpest annual moves came in 2022 and 2024: EBIT Margin tumbled 12886 bps in 2022, then soared 11703 bps in 2024.
• A 5-year view of EBIT Margin shows it stood at 89.13% in 2022, then rose by 5 bps to 85.03% in 2023, then soared by 138 bps to 32.0% in 2024, then tumbled by 324 bps to 71.69% in 2025, then soared by 141 bps to 29.41% in 2026.
• The last three EBIT Margin figures came in at 29.41% (Q1 2026), 71.69% (Q4 2025), and 26.61% (Q3 2025), per Business Quant data.